---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000002"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:03:45.557794+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora Pharmaceuticals receives Nasdaq extension to July 15, 2024 for bid price compliance

## Summary
- Nasdaq grants additional 180-day compliance period until July 15, 2024 for $1.00 minimum bid price rule.
- Company failed to regain compliance by original deadline of January 15, 2024; stock below $1 since July 2023.
- Extension conditioned on meeting market value of publicly held shares and other initial listing standards.
- Company evaluating reverse stock split to cure deficiency; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001372514-24-000002
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000002/0001372514-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000002/kprx-20240116.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000002
- JSON: https://secwatch.observer/filing/0001372514-24-000002.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000002.txt

## Key facts
- Listing & Compliance Notices
  KIORA PHARMACEUTICALS INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
  - Exchange: nasdaq
  - Notice: extension granted
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2), 5810(c)(3)(A)
  source text: January 16, 2024, Nasdaq notified the Company in writing (the “Extension Letter”) that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Bid Price Rule. Nasdaq’s determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company’s written notice to Nasdaq o
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000002/0001372514-24-000002-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.